The PRIMO Study-Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Chronic Kidney Disease Stage 3B/4.
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2014
At a glance
- Drugs Paricalcitol (Primary)
- Indications Kidney disorders; Left ventricular hypertrophy
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms PRIMO
- Sponsors Abbott Laboratories
- 31 Aug 2018 Biomarkers information updated
- 10 Apr 2012 Actual end date changed from 24 Jun 2010 to Mar 2012 as reported by ClinicalTrials.gov.
- 03 Mar 2012 Actual end date (Jul 2010) added as reported by European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History